Silverback Therapeutics, Inc. SBTX
5.87 0.00 (+0.00%)
At closeNov 9, 2022, 12:00 AM EST
5.82 Day range 6.15
52-week range unavailable
- Market cap
- 211.66M
- Shares out
- 36.06M
- Forward P/E
- -2.76
- Volume
- 116.69K
- Open
- 5.82
- Previous close
- 5.87
- Day's range
- 5.82 – 6.15
- Analysts
- Hold
- Price target
- 5.00 (-14.8%)
- Earnings date
- Nov 2, 2022
No chart data for this range yet.
Key statistics
- Enterprise value
- -58.27M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -59.46M
- Total cash
- 266.62M
- Total debt
- 215.00K
- Return on equity
- -28.50%
- Short % of float
- 3.95%
- 50-day average
- 5.39
- 200-day average
- 4.37
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00
Ratings (-1m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 2, 2022
Expected Nov 2, 2022. Consensus EPS estimate -0.34.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.62 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.67 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | -0.70 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.72 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 4, 2022 | Goldman Sachs | down | Buy | Neutral |
| Apr 1, 2022 | JonesTrading | down | Buy | Hold |
| Apr 1, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Apr 1, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 1, 2022 | Stifel | down | Buy | Hold |
| Nov 12, 2021 | SVB Leerink | main | — | Outperform |
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- silverbacktx.com
News
Stocks That Hit 52-Week Lows On Wednesday 
Stocks That Hit 52-Week Lows On Friday - Stocks That Hit 52-Week Lows On Friday
- Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022
Stocks That Hit 52-Week Lows On Monday - Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Thursday 
Stocks That Hit 52-Week Lows On Tuesday - Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on SBTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDRIA VENTURE INVESTMENTS, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 7, 2020 | 699,412 |
| HAWKINSON RUSS | Officer | Stock Award(Grant) | May 1, 2022 | 37,251 |
| HUNDER NAOMI | Officer | Stock Award(Grant) | May 1, 2022 | 54,427 |
| ODEGARD VALERIE | President | Stock Award(Grant) | May 1, 2022 | 61,639 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 7, 2020 | 0 |
| PIAZZA JONATHAN | Chief Financial Officer | Stock Award(Grant) | May 1, 2022 | 69,225 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 24.24% | 8,740,887 | 51.31M | Jun 29, 2022 |
| FMR, LLC | 10.31% | 3,718,452 | 21.83M | Jun 29, 2022 |
| Nextech Invest Ag | 5.30% | 1,910,029 | 11.21M | Jun 29, 2022 |
| K2 Principal Fund, L.P. | 4.28% | 1,541,706 | 9.05M | Jun 29, 2022 |
| Nantahala Capital Management, LLC | 3.84% | 1,386,138 | 8.14M | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 2.93% | 1,056,664 | 6.20M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.92% | 1,412,071 | 8.29M | Aug 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.02% | 729,100 | 4.28M | Jun 29, 2022 |
| Fidelity Growth Company K6 Fund | 0.99% | 356,242 | 2.09M | Aug 30, 2022 |
| Vanguard Extended Market Index Fund | 0.80% | 288,024 | 1.69M | Jun 29, 2022 |
| Fidelity Select Portfolios - Biotechnology | 0.76% | 275,209 | 1.62M | Aug 30, 2022 |
| Fidelity Series Growth Company Fund | 0.65% | 233,584 | 1.37M | Jun 29, 2022 |